Evommune's EVO756 Fails Phase 2b Trial for Chronic Urticaria
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Source: Newsfilter
Evommune Inc's stock dropped significantly, hitting a 20-day low, following the announcement of its EVO756 clinical trial results.
The Phase 2b trial for EVO756, aimed at treating moderate-to-severe chronic spontaneous urticaria, failed to meet its primary endpoint, with no significant change observed in the Urticaria Activity Score among 160 patients after 12 weeks. Despite this setback, Evommune plans to continue developing EVO756 for atopic dermatitis and migraine, with top-line data expected in Q3 2026, indicating the company's commitment to exploring new indications. Furthermore, Evommune maintains a strong financial position, ensuring operational stability through 2028, which supports its ongoing pipeline advancements.
The implications of this trial failure may affect investor sentiment, but the company's financial stability and plans for future development could provide a foundation for recovery in the long term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVMN
Wall Street analysts forecast EVMN stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.820
Low
35.00
Averages
38.60
High
42.00
Current: 12.820
Low
35.00
Averages
38.60
High
42.00
About EVMN
Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evommune Shares Plunge 38% After Drug Trial Failure
- Significant Stock Decline: Evommune's shares plummeted approximately 38% following the announcement that its lead drug candidate EVO756 failed to meet the primary endpoint in a Phase 2b trial, severely undermining investor confidence and potentially complicating future fundraising efforts.
- Insider Trading Investigation: Just a week before the trial failure was disclosed, CEO Luis C. Pena sold 7,438 shares for about $168,916, while CSO Jeegar Patel exercised and sold 1,488 options at $22.50 each, raising concerns over possible insider trading and legal repercussions.
- Increased Legal Risks: Levi & Korsinsky LLP is investigating whether Evommune insiders concealed material adverse information regarding the EVO756 trial outcome when submitting Form 144, which could expose the company to securities law violations and further legal challenges.
- Investor Rights Protection: Affected investors are encouraged to contact the law firm to discuss their legal rights, highlighting potential deficiencies in the company's transparency and compliance, which may further impact its market reputation.
See More
Evommune Executives Under Investigation for Insider Trading Ahead of Drug Trial Failure
- Stock Price Plunge: Evommune's announcement that its lead drug candidate EVO756 failed to meet the primary endpoint in a Phase 2b trial resulted in a significant 38% drop in share price, severely impacting investor confidence and potentially hindering future fundraising efforts.
- Executive Stock Sales: Just one week before the trial results were disclosed, CEO Luis C. Pena sold 7,438 shares at prices between $22.50 and $22.99, generating approximately $168,916, while CSO Jeegar Patel exercised options at $3.84 and sold them at $22.50, raising concerns about insider trading.
- Legal Investigation Initiated: Levi & Korsinsky LLP is investigating whether the executives concealed material adverse information regarding the EVO756 trial outcome when they submitted Form 144 filings, which could lead to legal liabilities for the company and its executives.
- Investor Rights Protection: Affected investors are encouraged to contact the law firm to discuss their legal rights, indicating that the company faces pressure regarding transparency and compliance, which may impact its future market performance and investor trust.
See More
Evommune Shares Drop 31% After Phase 2b Trial Misses Primary Endpoint
- Disappointing Trial Results: Evommune's shares fell approximately 31% in early Monday trading after the phase 2b trial for chronic spontaneous urticaria candidate EVO756 failed to meet its primary endpoint, indicating significant investor concern.
- Trial Design Details: In the trial, patients were administered one of three doses or a placebo, but none of the active dose cohorts showed a significant mean change in the Urticaria Activity Score over seven days at 12 weeks, highlighting the drug's insufficient efficacy.
- Future Data Release Plans: Evommune is slated to release top-line phase 2b data for EVO756 in atopic dermatitis in Q3, which could influence investor sentiment regarding the company's future potential and pipeline viability.
- Financial Performance Overview: The company reported a GAAP EPS of -$0.64, reflecting financial strain during the R&D phase, which may impact future funding and market confidence in Evommune's prospects.
See More
Evommune Reports Phase 2b Trial Results for EVO756
- Trial Results: Evommune announced top-line results from its Phase 2b trial of oral MRGPRX2 antagonist EVO756, which failed to meet its primary endpoint but confirmed safe and well-tolerated doses, indicating potential in chronic spontaneous urticaria patients.
- Trial Design: The randomized, double-blind, placebo-controlled, dose-ranging trial evaluated the efficacy and safety of EVO756, with participants receiving one of three active dose regimens or placebo, revealing no statistically significant change in Urticaria Activity Score over 12 weeks.
- Exploring New Indications: Despite the disappointing trial results, the company is evaluating EVO756 for additional indications and has initiated a Phase 2b trial for migraine prophylaxis, with patient dosing expected to commence imminently, demonstrating the company's commitment to exploring new therapies.
- Strong Financial Position: Evommune's robust cash position is projected to support operations through 2028, indicating a solid strategic foundation for advancing its pipeline of therapies targeting chronic inflammatory diseases.
See More
Evommune's Clinical Trial Fails to Meet Primary Endpoint
- Trial Results: Evommune's EVO756 failed to meet the primary endpoint in its Phase 2b trial for moderate-to-severe chronic spontaneous urticaria, with 160 patients showing no significant change in Urticaria Activity Score at 12 weeks, indicating a lack of efficacy that may impact future development strategies.
- Future Development Plans: Despite the disappointing trial results, Evommune plans to continue developing EVO756 for atopic dermatitis and migraine, with top-line data expected in Q3 2026, reflecting the company's ongoing confidence in exploring new indications.
- Strong Financial Position: Evommune reported a robust cash position that supports operations through 2028, providing financial stability to navigate the setback from the clinical trial failure and ensuring continued advancement of its pipeline.
- Drug Development Outlook: As the first oral small molecule antagonist targeting MRGPRX2, EVO756's failure in urticaria does not diminish its potential in other chronic inflammatory diseases, suggesting possible new market opportunities for the company.
See More
Evommune, Inc. Reports Q1 Financial Results
- Financial Performance: Evommune reported a Q1 GAAP EPS of -$0.64, indicating challenges in profitability; however, cash and cash equivalents rose to $307 million from $216.7 million at year-end 2025, reflecting some stability in financial management despite losses.
- Revenue Decline: The company reported zero revenue for Q1 2026, a significant drop from $3 million in the same period of 2025, primarily due to the lack of expected income from the strategic collaboration with Maruho, highlighting difficulties in market penetration and product commercialization.
- Clinical Trial Updates: Top-line data from the Phase 2b trials of EVO756 for chronic spontaneous urticaria and atopic dermatitis is on track for June 2026 and Q3 2026, respectively, demonstrating ongoing commitment to R&D despite revenue pressures.
- Future Initiatives: Plans to initiate a Phase 2b dose-ranging clinical trial for EVO756 in migraine prophylaxis in mid-2026 indicate a proactive approach to developing new therapies, showing that the company is still seeking innovative breakthroughs despite its current financial challenges.
See More
Evommune Shares Plunge 38% After Drug Trial Failure
- Significant Stock Decline: Evommune's shares plummeted approximately 38% following the announcement that its lead drug candidate EVO756 failed to meet the primary endpoint in a Phase 2b trial, severely undermining investor confidence and potentially complicating future fundraising efforts.
- Insider Trading Investigation: Just a week before the trial failure was disclosed, CEO Luis C. Pena sold 7,438 shares for about $168,916, while CSO Jeegar Patel exercised and sold 1,488 options at $22.50 each, raising concerns over possible insider trading and legal repercussions.
- Increased Legal Risks: Levi & Korsinsky LLP is investigating whether Evommune insiders concealed material adverse information regarding the EVO756 trial outcome when submitting Form 144, which could expose the company to securities law violations and further legal challenges.
- Investor Rights Protection: Affected investors are encouraged to contact the law firm to discuss their legal rights, highlighting potential deficiencies in the company's transparency and compliance, which may further impact its market reputation.
See More
Evommune Executives Under Investigation for Insider Trading Ahead of Drug Trial Failure
- Stock Price Plunge: Evommune's announcement that its lead drug candidate EVO756 failed to meet the primary endpoint in a Phase 2b trial resulted in a significant 38% drop in share price, severely impacting investor confidence and potentially hindering future fundraising efforts.
- Executive Stock Sales: Just one week before the trial results were disclosed, CEO Luis C. Pena sold 7,438 shares at prices between $22.50 and $22.99, generating approximately $168,916, while CSO Jeegar Patel exercised options at $3.84 and sold them at $22.50, raising concerns about insider trading.
- Legal Investigation Initiated: Levi & Korsinsky LLP is investigating whether the executives concealed material adverse information regarding the EVO756 trial outcome when they submitted Form 144 filings, which could lead to legal liabilities for the company and its executives.
- Investor Rights Protection: Affected investors are encouraged to contact the law firm to discuss their legal rights, indicating that the company faces pressure regarding transparency and compliance, which may impact its future market performance and investor trust.
See More
Evommune Shares Drop 31% After Phase 2b Trial Misses Primary Endpoint
- Disappointing Trial Results: Evommune's shares fell approximately 31% in early Monday trading after the phase 2b trial for chronic spontaneous urticaria candidate EVO756 failed to meet its primary endpoint, indicating significant investor concern.
- Trial Design Details: In the trial, patients were administered one of three doses or a placebo, but none of the active dose cohorts showed a significant mean change in the Urticaria Activity Score over seven days at 12 weeks, highlighting the drug's insufficient efficacy.
- Future Data Release Plans: Evommune is slated to release top-line phase 2b data for EVO756 in atopic dermatitis in Q3, which could influence investor sentiment regarding the company's future potential and pipeline viability.
- Financial Performance Overview: The company reported a GAAP EPS of -$0.64, reflecting financial strain during the R&D phase, which may impact future funding and market confidence in Evommune's prospects.
See More
Evommune Reports Phase 2b Trial Results for EVO756
- Trial Results: Evommune announced top-line results from its Phase 2b trial of oral MRGPRX2 antagonist EVO756, which failed to meet its primary endpoint but confirmed safe and well-tolerated doses, indicating potential in chronic spontaneous urticaria patients.
- Trial Design: The randomized, double-blind, placebo-controlled, dose-ranging trial evaluated the efficacy and safety of EVO756, with participants receiving one of three active dose regimens or placebo, revealing no statistically significant change in Urticaria Activity Score over 12 weeks.
- Exploring New Indications: Despite the disappointing trial results, the company is evaluating EVO756 for additional indications and has initiated a Phase 2b trial for migraine prophylaxis, with patient dosing expected to commence imminently, demonstrating the company's commitment to exploring new therapies.
- Strong Financial Position: Evommune's robust cash position is projected to support operations through 2028, indicating a solid strategic foundation for advancing its pipeline of therapies targeting chronic inflammatory diseases.
See More
Evommune's Clinical Trial Fails to Meet Primary Endpoint
- Trial Results: Evommune's EVO756 failed to meet the primary endpoint in its Phase 2b trial for moderate-to-severe chronic spontaneous urticaria, with 160 patients showing no significant change in Urticaria Activity Score at 12 weeks, indicating a lack of efficacy that may impact future development strategies.
- Future Development Plans: Despite the disappointing trial results, Evommune plans to continue developing EVO756 for atopic dermatitis and migraine, with top-line data expected in Q3 2026, reflecting the company's ongoing confidence in exploring new indications.
- Strong Financial Position: Evommune reported a robust cash position that supports operations through 2028, providing financial stability to navigate the setback from the clinical trial failure and ensuring continued advancement of its pipeline.
- Drug Development Outlook: As the first oral small molecule antagonist targeting MRGPRX2, EVO756's failure in urticaria does not diminish its potential in other chronic inflammatory diseases, suggesting possible new market opportunities for the company.
See More
Evommune, Inc. Reports Q1 Financial Results
- Financial Performance: Evommune reported a Q1 GAAP EPS of -$0.64, indicating challenges in profitability; however, cash and cash equivalents rose to $307 million from $216.7 million at year-end 2025, reflecting some stability in financial management despite losses.
- Revenue Decline: The company reported zero revenue for Q1 2026, a significant drop from $3 million in the same period of 2025, primarily due to the lack of expected income from the strategic collaboration with Maruho, highlighting difficulties in market penetration and product commercialization.
- Clinical Trial Updates: Top-line data from the Phase 2b trials of EVO756 for chronic spontaneous urticaria and atopic dermatitis is on track for June 2026 and Q3 2026, respectively, demonstrating ongoing commitment to R&D despite revenue pressures.
- Future Initiatives: Plans to initiate a Phase 2b dose-ranging clinical trial for EVO756 in migraine prophylaxis in mid-2026 indicate a proactive approach to developing new therapies, showing that the company is still seeking innovative breakthroughs despite its current financial challenges.
See More
